Company / Cost of Revenue
Amneal Pharmaceuticals, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.9B
FY2025
5-year range
$1.1B / $1.9B
FY2021-FY2025
Trend
+7.4%
vs FY2024
Sector context
#16 of 85
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s cost of revenue of $1.9B is higher than 81% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $421M in FY2018 to $1.9B in FY2025.
Based on SEC 10-K filings.
$1.9B in FY2025 with a 5-year CAGR of +15.2%. Top quartile in the Health Care sector.
Increased from $1.3B to $1.9B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +10.1%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
-3.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.2%, indicating consistent growth.
- In FY2025, cost of revenue increased 7.4% year-over-year.
- Ranks #16 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9B | +7.4% |
| FY2024 | $1.8B | +33.9% |
| FY2023 | $1.3B | -7.2% |
| FY2022 | $1.4B | +24.4% |
| FY2021 | $1.1B | +22.2% |
| FY2020 | $938.8M | +85.0% |
| FY2019 | $507.5M | +20.6% |
| FY2018 | $420.8M | -17.1% |
| FY2017 | $507.5M | +20.6% |
| FY2016 | $420.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026